A recent study has found that pairing cannabidiol (CBD) with fibroblast growth factor receptor (FGFR) inhibitors could provide a more effective therapy for treating colorectal cancer, which is one of the deadliest forms of cancers worldwide. The researchers tested the effects of CBD and the FGFR inhibitor AZD4547 on colorectal cancer cells, focusing on the NCI-H716 line, which shows high FGFR2 expression. Further analysis revealed that the enhanced impact was tied to endoplasmic reticulum (ER) stress, a cellular pathway known to regulate apoptosis. RNA sequencing and gene silencing experiments confirmed ER stress as a key mechanism behind the combination therapy’s success. By boosting the efficacy of FGFR inhibitors, CBD could help overcome resistance and improve outcomes for colorectal cancer patients, a group that urgently needs new treatment strategies.